Details for New Drug Application (NDA): 212727
✉ Email this page to a colleague
The generic ingredient in DOXAZOSIN MESYLATE is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.
Summary for 212727
| Tradename: | DOXAZOSIN MESYLATE |
| Applicant: | Rising |
| Ingredient: | doxazosin mesylate |
| Patents: | 0 |
Pharmacology for NDA: 212727
| Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for 212727
Suppliers and Packaging for NDA: 212727
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 212727 | ANDA | Rising Pharma Holdings, Inc. | 16571-165 | 16571-165-01 | 100 TABLET in 1 BOTTLE (16571-165-01) |
| DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 212727 | ANDA | Rising Pharma Holdings, Inc. | 16571-166 | 16571-166-01 | 100 TABLET in 1 BOTTLE (16571-166-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 1MG BASE | ||||
| Approval Date: | Mar 15, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 2MG BASE | ||||
| Approval Date: | Mar 15, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 4MG BASE | ||||
| Approval Date: | Mar 15, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
